N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells

European Journal of Immunology

Volumn 38, Issue 6, 2008, Pages 1493-1502

  Mor, Adi ^a   Keren, Gad ^a   Kloog, Yoel ^a   George, Jacob ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoimmunity; Diabetes mellitus; Foxp3; Ras; Regulatory T cells

Indexed keywords

FARNESYLTHIOSALICYLIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; H RAS PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; K RAS PROTEIN; PROTEIN N RAS; RAS PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; DRUG DERIVATIVE; ENZYME INHIBITOR; FARNESOL; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; PROTEIN P21; SALICYLIC ACID DERIVATIVE; TRANSCRIPTION FACTOR NFAT;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DIABETES MELLITUS; EFFECTOR CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; RISK REDUCTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL NUCLEUS; COCULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONONUCLEAR CELL; RNA INTERFERENCE; SPLEEN; T LYMPHOCYTE; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL NUCLEUS; COCULTURE TECHNIQUES; DIABETES MELLITUS; ENZYME INHIBITORS; FARNESOL; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; JURKAT CELLS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NFATC TRANSCRIPTION FACTORS; PROTO-ONCOGENE PROTEINS P21(RAS); RNA INTERFERENCE; SALICYLIC ACIDS; SPLEEN; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TRANSFECTION; UP-REGULATION;

EID: 49649099238     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200838292     Document Type: Article

References (22)

1. + Tregs: Limiting collateral damage. J. Clin. Invest. 2004. 114: 1372-1378.
2. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004. 22: 531-562.
3. Crispin, J. C., Alcocer-Varela, J., de Pablo, P., Martinez, A., Richaud-Patin, Y. and Alarcon-Segovia, D., Immunoregulatory defects in patients with systemic lupus erythematosus in clinical remission. Lupus 2003. 12: 386-393.
4. Kukreja, A., Cost, G., Marker, J., Zhang, C., Sun, Z., Lin-Su, K., Ten, S. et al., Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 2002. 109: 131-140.
5. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004. 199: 971-979.
6. + regulatory T cells. Nat. Immunol. 2003. 4: 330-336.
7. Wu, Y., Borde,M., Heissmeyer, V., Feuerer, M., Lapan, A. D., Stroud, J. C., Bates, D. L. et al., FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006. 126: 375-387.
8. Campbell, D. J. and Ziegler, S. F., FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat. Rev. Immunol. 2007. 7: 305-310.
9. Marson, A., Kretschmer, K., Frampton, G. M., Jacobsen, E. S., Polansky, J. K., MacIsaac, K. D., Levine, S. S. et al., Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007. 445: 931-935.
10. Genot, E. and Cantrell, D. A., Ras regulation and function in lymphocytes. Curr. Opin. Immunol. 2000. 12: 289-294.
11. Schubbert, S., Shannon, K. and Bollag, G., Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 2007. 7: 295-308.
12. Zebisch, A., Czernilofsky, A. P., Keri, G., Smigelskaite, J., Sill, H. and Troppmair, J., Signaling through RAS-RAF-MEK-ERK: From basics to bedside. Curr. Med. Chem. 2007. 14: 601-623.
13. Oliveira, J. B., Bidere, N., Niemela, J. E., Zheng, L., Sakai, K., Nix, C. P., Danner, R. L. et al., NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc. Natl. Acad. Sci. USA 2007. 104: 8953-8958.
14. Karussis, D., Abramsky, O., Grigoriadis, N., Chapman, J., Mizrachi-Koll, R., Niv, H. and Kloog, Y., The Ras-pathway inhibitor, S-trans-transfarnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis. J. Neuroimmunol. 2001. 120: 1-9.
15. Marks, R. E., Ho, A. W., Robbel, C., Kuna, T., Berk, S. and Gajewski, T. F., Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood 2007. 110: 1982-1988.
16. + regulatory T cells. J. Immunol. 2006. 177: 6603-6612.
17. Genot, E., Cleverley, S., Henning, S. and Cantrell, D., Multiple p21ras effector pathways regulate nuclear factor of activated T cells. EMBO J. 1996. 15: 3923-3933.
18. Katzav, A., Kloog, Y., Korczyn, A. D., Niv, H., Karussis, D. M., Wang, N., Rabinowitz, R. et al., Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS). Clin. Exp. Immunol. 2001. 126: 570-577.
19. Kloog, Y. and Cox, A. D., RAS inhibitors: Potential for cancer therapeutics. Mol. Med. Today 2000. 6: 398-402.
20. Thomas, D., Zaccone, P. and Cooke, A., The role of regulatory Tcell defects in type I diabetes and the potential of these cells for therapy. Rev. Diabet. Stud. 2005. 2: 9-18.
21. Yang, Z., Zhou, Z., Huang, G., Ling, H., Yan, X., Peng, J. and Li, X., The CD4(+) regulatory T-cells is decreased in adults with latent autoimmune diabetes. Diabetes Res. Clin. Pract. 2007. 76: 126-131.
22. Goldberg, L. and Kloog, Y., A Ras inhibitor tilts the balance between Rac and Rho and blocks PI3-kinase-dependent glioblastoma cell migration. Cancer Res. 2006. 66: 11709-11717.